↓ Skip to main content

Dove Medical Press

Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma

Overview of attention for article published in Drug Design, Development and Therapy, May 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
30 Mendeley
Title
Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma
Published in
Drug Design, Development and Therapy, May 2018
DOI 10.2147/dddt.s147389
Pubmed ID
Authors

Eric D Bateman, Christopher O’Brien, Paul Rugman, Sally Luke, Stefan Ivanov, Mohib Uddin

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 30 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 13%
Student > Master 4 13%
Student > Bachelor 3 10%
Other 2 7%
Professor 2 7%
Other 5 17%
Unknown 10 33%
Readers by discipline Count As %
Medicine and Dentistry 10 33%
Biochemistry, Genetics and Molecular Biology 3 10%
Immunology and Microbiology 2 7%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Nursing and Health Professions 1 3%
Other 4 13%
Unknown 9 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 November 2019.
All research outputs
#4,838,109
of 25,382,440 outputs
Outputs from Drug Design, Development and Therapy
#304
of 2,268 outputs
Outputs of similar age
#87,089
of 339,234 outputs
Outputs of similar age from Drug Design, Development and Therapy
#8
of 58 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 339,234 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.